Bits of Yolanda Y

Understanding Hidradenitis Suppurativa: A Technical Overview 

Hidradenitis Suppurativa (HS) is a chronic, inflammatory skin condition that often goes underdiagnosed and misunderstood. It is characterized by painful nodules, abscesses, and sinus tracts that typically occur in areas where skin rubs together—such as the armpits, groin, buttocks, and under the breasts.

While HS is not contagious, it can have a profound impact on quality of life, affecting physical comfort, mobility, and emotional well-being.

 

Pathophysiology

HS is believed to result from follicular occlusion—a blockage of hair follicles—leading to inflammation, rupture, and secondary bacterial infection. This process triggers a chronic immune response, involving elevated levels of inflammatory cytokines such as TNF-α, IL-1β, and IL-17.

Genetic predisposition plays a role, with mutations in the γ-secretase complex genes (e.g., NCSTN, PSENEN, PSEN1) linked to familial HS. Hormonal influences and dysbiosis of skin microbiota are also under investigation.

 

Clinical Staging

The Hurley staging system is commonly used to classify HS severity:

 

Stage I: Single or multiple abscesses without sinus tracts or scarring.

Stage II: Recurrent abscesses with sinus tract formation and scarring, widely separated lesions.

Stage III: Diffuse or near-diffuse involvement with multiple interconnected sinus tracts and abscesses.

 

Diagnosis

HS is diagnosed clinically based on:

Typical lesions (nodules, abscesses, sinus tracts, scarring)

locations (intertriginous areas)

Chronicity and recurrence (at least twice in 6 months)

No specific laboratory test confirms HS, but imaging (ultrasound or MRI) can help assess deep tissue involvement.

 

Management Strategies

Treatment is multimodal and tailored to disease severity:

Lifestyle Modifications: Weight management, smoking cessation, and wearing loose clothing to reduce friction.

 

Medical Therapy:

§  Topical clindamycin for mild disease.

§  Oral tetracyclines or clindamycin + rifampin for moderate disease.

§  Biologics such as adalimumab (FDA-approved) and emerging IL-17 inhibitors for severe disease.

 

Procedural Interventions:

§  Incision and drainage (for acute relief, though recurrence is common).

§  Laser hair removal to reduce follicular occlusion.

§  Wide surgical excision for advanced disease.

 

Emerging Therapies

Recent research is exploring:

§  JAK inhibitors for immune modulation.

§  Microbiome-targeted therapies to restore skin balance.

§  Stem cell-based regenerative approaches for tissue repair.

 

Psychosocial Considerations

HS is associated with depression, anxiety, and social isolation. Integrating mental health support into treatment plans is essential for holistic care.

 

Conclusion

Hidradenitis Suppurativa is more than a skin condition—it’s a systemic, inflammatory disease that requires early recognition, multidisciplinary management, and compassionate care. Advances in biologics and targeted therapies offer hope for improved outcomes; however, patient education and support remain cornerstones of effective treatment.

 

References

 

§  Alikhan A, Sayed C, Alavi A, et al. North American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations. J Am Acad Dermatol. 2019;81(1):76–90.

§  Zouboulis CC, Desai N, Emtestam L, et al. European S1 guideline for the treatment of hidradenitis suppurativa/acne inversa. J Eur Acad Dermatol Venereol. 2015;29(4):619–644.

§  Jemec GBE. Clinical practice. Hidradenitis suppurativa. N Engl J Med. 2012;366:158–164.

§  Canadian Hidradenitis Suppurativa Foundation. *Practical Guidelines for Managing Patients